Our Focus

At Rivus, we are focused on advancing cardiometabolic health by developing new oral medicines. Our primary focus is on MASH, a serious, chronic liver disease that is driven by excess liver fat and inflammation. There is a significant, growing unmet need for new therapies that address the underlying drivers of this disease. We are advancing our lead therapy HU6 as a potential best-in-class MASH therapy that is uniquely positioned to address these unmet needs. Our pipeline also includes RV-8451, the industry's first muscle-preserving, oral GLP-1, in preclinical development for obesity. We are driven by our mission to advance cardiometabolic health as we focus on addressing significant unmet needs in MASH and obesity.